Early Pediatric Anthracycline Cardiotoxicity: Managed by Serial Heart and Bone Marrow Transplantation

Journal of Heart and Lung Transplantation

Volumn 26, Issue 6, 2007, Pages 658-660

  Mangat, Jasveer S ^a   Rao, Kanchan ^a   Kingston, Judith ^a   Veys, Paul ^a   Amrolia, Persis ^a   Burch, Michael ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMSACRINE; ANTHRACYCLINE; ANTICOAGULANT AGENT; BASILIXIMAB; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISOLONE; TACROLIMUS; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CARDIOTOXICITY; CASE REPORT; CHILDHOOD LEUKEMIA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PEDIATRIC SURGERY; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD; HEART TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; PANCYTOPENIA; RECURRENCE; SURVIVORS;

EID: 34249305495     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.03.014     Document Type: Article

References (6)

1. Ward K.M., Binns H., Chin C., Webber S.A., Canter C.E., and Pahl E. Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. J Heart Lung Transplant 23 (2004) 1040-1045
2. Levitt G., Bunch K., Rogers C.A., and Whitehead B. Cardiac transplantation in childhood cancer survivors in Great Britain. Eur J Cancer Part A 32 (1996) 826-830
3. Webb D.K.H., Harrison G., Stevens R.F., Gibson B.G., Hann I.M., and Wheatley K. Relationship between age at diagnosis, clinical features and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukaemia. Blood 15 (2001) 1714-1720
4. Stahnke K., Boos J., Bender-Gotze C., Ritter J., Zimmermann M., and Creutzig U. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 12 (1998) 1534-1538
5. Alonzo T.A., Wells R.J., Woods W.G., et al. Post remission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era. Leukemia 19 (2005) 965-970
6. Stevens R.F., Hann I.M., Wheatley K., and Gray R.G. Marked improvement in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 101 (1998) 130-140